Corline Biomedical AB (CLBIO.ST)
SEK 8.98
(-3.23%)
SEK 8.98
(-3.23%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 30.16 Million SEK | 47.9% |
| 2022 | 20.39 Million SEK | 83.18% |
| 2021 | 11.13 Million SEK | -36.76% |
| 2020 | 17.6 Million SEK | 5.51% |
| 2019 | 16.68 Million SEK | 25.27% |
| 2018 | 13.32 Million SEK | 57.11% |
| 2017 | 8.47 Million SEK | -33.08% |
| 2016 | 12.67 Million SEK | 43.18% |
| 2015 | 8.84 Million SEK | 50.17% |
| 2014 | 5.89 Million SEK | -8.56% |
| 2013 | 6.44 Million SEK | -3.78% |
| 2012 | 6.69 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 9.84 Million SEK | 49.75% |
| 2024 Q1 | 6.57 Million SEK | -15.84% |
| 2023 Q2 | 7.88 Million SEK | 5.42% |
| 2023 Q1 | 7.47 Million SEK | 10.74% |
| 2023 FY | 30.16 Million SEK | 47.9% |
| 2023 Q3 | 6.99 Million SEK | -11.24% |
| 2023 Q4 | 7.81 Million SEK | 11.62% |
| 2022 Q4 | 6.75 Million SEK | 35.71% |
| 2022 FY | 20.39 Million SEK | 83.18% |
| 2022 Q3 | 4.97 Million SEK | 11.85% |
| 2022 Q2 | 4.44 Million SEK | 5.43% |
| 2022 Q1 | 4.22 Million SEK | 9947.62% |
| 2021 Q1 | 3.71 Million SEK | -16.15% |
| 2021 Q4 | 42 Thousand SEK | -98.83% |
| 2021 Q2 | 3.78 Million SEK | 1.69% |
| 2021 Q3 | 3.59 Million SEK | -4.87% |
| 2021 FY | 11.13 Million SEK | -36.76% |
| 2020 Q1 | 4.99 Million SEK | 9.16% |
| 2020 Q3 | 3.07 Million SEK | -39.81% |
| 2020 Q4 | 4.43 Million SEK | 44.21% |
| 2020 FY | 17.6 Million SEK | 5.51% |
| 2020 Q2 | 5.1 Million SEK | 2.28% |
| 2019 Q2 | 4.55 Million SEK | 5.53% |
| 2019 Q1 | 4.32 Million SEK | -47.45% |
| 2019 Q3 | 3.23 Million SEK | -29.06% |
| 2019 FY | 16.68 Million SEK | 25.27% |
| 2019 Q4 | 4.57 Million SEK | 41.43% |
| 2018 FY | 13.32 Million SEK | 57.11% |
| 2018 Q4 | 8.22 Million SEK | 570.47% |
| 2018 Q1 | 2.09 Million SEK | 19.78% |
| 2018 Q3 | 1.22 Million SEK | -31.12% |
| 2018 Q2 | 1.78 Million SEK | -15.04% |
| 2017 FY | 8.47 Million SEK | -33.08% |
| 2017 Q2 | 2.76 Million SEK | -27.58% |
| 2017 Q3 | 1.06 Million SEK | -61.49% |
| 2017 Q4 | 1.74 Million SEK | 64.38% |
| 2017 Q1 | 3.81 Million SEK | 45.39% |
| 2016 Q2 | 3.14 Million SEK | -16.54% |
| 2016 FY | 12.67 Million SEK | 43.18% |
| 2016 Q1 | 3.76 Million SEK | 32.29% |
| 2016 Q4 | 2.62 Million SEK | -16.57% |
| 2016 Q3 | 3.14 Million SEK | 0.16% |
| 2015 Q4 | 2.84 Million SEK | 58.24% |
| 2015 FY | 8.84 Million SEK | 50.17% |
| 2015 Q1 | 1.62 Million SEK | 1.9% |
| 2015 Q2 | 2.58 Million SEK | 58.87% |
| 2015 Q3 | 1.79 Million SEK | -30.4% |
| 2014 Q3 | 1.33 Million SEK | -8.52% |
| 2014 Q4 | 1.59 Million SEK | 19.47% |
| 2014 FY | 5.89 Million SEK | -8.56% |
| 2014 Q2 | 1.45 Million SEK | 0.0% |
| 2013 FY | 6.44 Million SEK | -3.78% |
| 2012 FY | 6.69 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Asarina Pharma AB (publ) | 14.65 Million SEK | -105.883% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 90.617% |
| NextCell Pharma AB | -576.01 Thousand SEK | 5337.327% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -6.502% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 91.564% |
| AcouSort AB (publ) | 25.87 Million SEK | -16.587% |
| OncoZenge AB (publ) | 15.9 Million SEK | -89.676% |
| Xintela AB (publ) | 57.31 Million SEK | 47.365% |
| Ziccum AB (publ) | 27.87 Million SEK | -8.214% |
| Active Biotech AB (publ) | 44.8 Million SEK | 32.674% |
| Alzinova AB (publ) | 36.39 Million SEK | 17.112% |
| Amniotics AB (publ) | 29.07 Million SEK | -3.77% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 90.176% |
| BioArctic AB (publ) | 89.62 Million SEK | 66.341% |
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 98.008% |
| Camurus AB (publ) | 1.05 Billion SEK | 97.153% |
| Cantargia AB (publ) | 290.01 Million SEK | 89.598% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -37.785% |
| CombiGene AB (publ) | 44.14 Million SEK | 31.66% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 78.902% |
| Genovis AB (publ.) | 88.19 Million SEK | 65.795% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 73.784% |
| Mendus AB (publ) | 129.13 Million SEK | 76.639% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -315.08% |
| Kancera AB (publ) | 63.07 Million SEK | 52.173% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -446.621% |
| LIDDS AB (publ) | 27.75 Million SEK | -8.706% |
| Lipum AB (publ) | 37.3 Million SEK | 19.136% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -315.881% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 77.803% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -83.94% |
| Saniona AB (publ) | 1.07 Million SEK | -2701.114% |
| Simris Alg AB (publ) | 38.64 Million SEK | 21.93% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 83.4% |
| Intervacc AB (publ) | 79.78 Million SEK | 62.188% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | 29.236% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -70.605% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 48.014% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 63.727% |
| Aptahem AB (publ) | 10.01 Million SEK | -201.29% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 77.603% |
| Fluicell AB (publ) | 28.61 Million SEK | -5.42% |
| Biovica International AB (publ) | 133.72 Million SEK | 77.44% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -52.441% |
| Abliva AB (publ) | 27.86 Million SEK | -8.261% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 84.409% |
| 2cureX AB (publ) | 36.51 Million SEK | 17.389% |
| I-Tech AB | 40.14 Million SEK | 24.858% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 96.49% |
| Cyxone AB (publ) | 28.21 Million SEK | -6.926% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 72.416% |
| Biosergen AB | 26.8 Million SEK | -12.529% |
| Nanologica AB (publ) | 69.88 Million SEK | 56.833% |
| SynAct Pharma AB | 224.49 Million SEK | 86.562% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | 31.71% |
| BioInvent International AB (publ) | 441.4 Million SEK | 93.165% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -25.94% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 89.588% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -283.999% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 72.801% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -105.224% |